PFE - Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why | Benzinga
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.
In the first study, PAS-004 exhibited dose-dependent antitumor efficacy in the lung cancer NCI-H1299 cell-line-derived xenograft model. PAS-004 at dose levels of 10 mg/kg and 5 mg/kg, once daily, significantly inhibited tumor growth compared ...